# Endoshunt

We Give Trauma Surgeons the Gift of TIME so They can Give Trauma Patients the Gift of LIFE

- Canonical URL: https://wefunder.com/endoshunt
- Entity ID: wefunder:company:125982
- Last updated: 2026-06-11T23:53:33Z
- Generated at: 2026-06-12T03:32:53Z

## Quick facts
- Novel size adjustable shunting device, ensuring patients' blood continues to flow to where it should
- Proven targeted hemorrhage control in animal model's IVC and aorta for >30-minutes
- Endovascular access to radically reduce blood loss during trauma surgery
- Clinically driven with 500+ customer discovery interviews and the advisement of Dr. Thomas Scalea
- Industry leading medical device development leadership experience from fortune 500 companies
- Multiple awards received including the Medical Device Innovation Award from HealthTech Arkansas
- Regulatory pathway built by the experts responsible for predicate device's FDA 510(k) clearance
- Strong industry partners that enable quality, manufacturing, and legal organizational success

## Active fundraises
- wefunder:fundraise:73879: 4(a)(6) open (USD)

## Story
Imagine if America's fifth largest city, Phoenix Arizona, disappeared overnight. That horrifying tragedy pales in comparison to the number of lives lost worldwide every single year due to uncontrolled abdominal bleeding. Backed by mHUB, Vibrant Memphis, and Epicenter Memphis, EndoShunt is on a mission to end these preventable deaths by giving trauma surgeons the gift of time so they can give trauma patients the gift of life.The sad reality is that the time to death from abdominal bleeding is often shorter than the time it takes to access the sites of the injury - leaving our surgeons in the helpless position of knowing how to save a life while lacking the tools they need to do so.Trauma is now the leading cause of death for individuals under the age of forty-six worldwide and abdominal hemorrhage is responsible for ~1.75M deaths every year. Causes like violent crimes, car accidents, or even complications during surgery indiscriminately impact younger individuals robbing individuals of their lives, families of their loved ones, and communities of their futures.Three of every five individuals lucky enough to survive suffer from life altering complications and nearly a year of painful recovery due to the secondary trauma caused by current treatment options. In more than five hundred healthcare interviews this problem has rung true. We have heard heartbreaking stories about times when patients were unable to return to their loved ones because we lacked the tools needed to save them.This industry needs a solution and EndoShunt is that solution.We empower surgeons with a new way to gain temporary, targeted occlusion over abdominal hemorrhage. Our device is inserted in the femoral artery or vein and traced to the Inferior Vena Cava (IVC) or aorta where it can be deployed to occlude blood flow from the inside. As our surgeons learn more, they can resize the device to only occlude the hemorrhage site - ensuring their patient's blood continues to flow to where it should without flowing out of where it shouldn't.Once the injury has been repaired, our device can be recaptured into its catheter and completely removed from the body - drastically reducing long-term risk for infection or future complications. To date, we have effectively proven hemorrhage control in the aorta and the IVC. We have tested our prototypes in simulation (in vitro) and in porcine animal models (in vivo) demonstrating effectiveness in each system. In our simulations, our patients lost blood at a rate that could result in death in just two minutes. However, with EndoShunt surgeons effectively stopped hemorrhage in as little as thirty-seconds! Of equal importance, they maintained this control over the life of the experiment - buying themselves the time they need to make lifesaving repairs. Our competitors cannot offer a comprehensive solution for the trauma centers, surgeons, nor patients.Packing or other external pressure alternatives:Examples - packing, sponges, ResQ FoamExtremely invasive, external pressure on the injury siteNo presurgical access to hemorrhage controlLimited clinical effectivenessReduce application in the IVCCan impair surgical successCan leave behind materials causing long-term complications in patientsCross ClampingExtremely invasiveNo presurgical access to hemorrhage controlNo ability for targeted occlusion, goes upstream of the injury and cuts off blood flow to the rest of the bodyNot safe for extended use due to tissue starvation of oxygen. Extended use can lead to complications as serious as blood poisoning, amputation, or organ failureBalloon Occlusion - REBOAOnly applicable for arterial injuries - only addressing ~half of the observable cases in healthcareNo ability for targeted occlusion, goes upstream of the injury and cuts off blood flow to the rest of the bodyNot safe for extended use due to tissue starvation of oxygen. Extended use can lead to complications as serious a blood poisoning, amputation, or organ failureEndoShuntEnables surgeons to gain presurgical control over abdominal hemorrhageCan be deployed in the IVC and aorta - effectively addressing all abdominal hemorrhage injury codesTargeted occlusion through size adjustable shunting controls (20cm <-> 5cm) - ensuring patient's blood can continue to flow to where it should without flowing out of where it shouldn't.Buys surgeons time to make definitive repairs while reducing risk for major morbidities or complicationsTemporary application - can be retracted into its catheter and safely removed from the patientDon't just take our word for it though. Trauma surgeons and trauma centers throughout the United States recognize the value EndoShunt will bring to the market. To further substantiate this support, Dr. Thomas Scalea, the leading trauma surgeon in the U.S., has recently joined EndoShunt's advisory board to help ensure our success. These professionals are eager to use EndoShunt and improve their patient outcomes in the near future!In a perfect world there would be no need for a product like EndoShunt, but this is a far from perfect world. We have leveraged the Trauma Quality Improvement Program (TQIP) dataset to accurately define our market sizing. Beachhead: $366MInjuries to the IVC or branching IVC vessels and organsGaining access to injury site during surgery is challenging prior to patient bleeding to deathEndovascular hemorrhage control before surgery could be the difference between life and deathU.S. Trauma Market: $612MAll relevant abdominal ICD10-S35 (vascular) and ICD10-S36 (solid organ) injury codesInjuries to the arterial vasculature and major solid organs in the abdomenInternational Trauma Markets: $10.5BEurope (EU MDR): $323MAsia (APEC, CDSCO): $4.1BSouth America (LATAM): $183MAfrica (SAHPRA): $5.8BTherapeutic Area Expansion: $60BThree additional therapeutic areas that have expressed interest during customer discoveryGreater detail related to EndoShunt's product pipeline is available upon request EndoShunt's holistic benefits accrue to the trauma community and will result in commercialization success. For our patients, EndoShunt...Reduces mortality through presurgical hemorrhage control and increased injury use casesReduces morbidity through targeted occlusion and continued blood flowReduces recovery time through decreased complicationsFor our surgeons, EndoShunt...Provides presurgical hemorrhage control through endovascular application - making definitive repair steps cleaner, less chaotic, and quickerProvides targeted hemorrhage control - allowing for increased time for successful repair while reducing complication risk associated with blood poisoning, amputation, or organ failureProvides a seamless fit within clinical process flows - eliminating resistance due to behavioral change managementFor our trauma centers, EndoShunt...Offers competitive pricing while improving functionality and financial outcomesEnsures access to ~$26k in existing reimbursement per patientEnables access to ~$4.0B in additional care opportunities that cannot be accessed due to the mortality limitations of current treatment alternativesAdditional financial information including pricing, margin, financial modeling, and market capture are available upon request (info@EndoShunt.com). Our organization is pursuing categorically defining intellectual property. In 2022, we filed for protection over the category of "temporary endovascular shunting" - enabling a platform to grow into increasing use cases throughout numerous therapeutic areas. We've ensured our freedom to operate and developed key design features that will enable us to capture market share for decades to come. They say you invest in a team first and a product second, but EndoShunt is truly lucky enough to have both. Tyler Zanon, CEO:Decade of cradle-to-grave medical device experienceHistory of leading innovation & R&D product development teams responsible for dozens of product launches in healthcareMaster of Public Health (MPH) & Project Management Professional (PMP)Leads EndoShunt's organizational development including project management, capital expenditure, financial modeling & planning, organizational planning & personnel onboarding, and eQMS & regulatory body applicationsMichael Finn-Henry, CTO:Engineering expert with experience in catheter based medical device developmentHistory in successful medical device R&D and technology transferPhD candidate at Harvard University in mechanical engineeringLeads EndoShunt's technical development including product development, intellectual property, and third-party manufacturing relationshipsDr. Milad Behbahaninia, CMO:Dual certified general and trauma surgeonExperience in surgical management of abdominal hemorrhageBackground in biomedical engineering - ensuring strong definition of user needs and proper addressing of critical design controls to mitigate possible failure modesActively leads EndoShunt's medical discovery efforts including use cases and market sizing, customer discovery & product-market fit, and future real-world evidence protocols during pilot launchDr. Jeremy Levin, CSO:Dual certified trauma and acute care surgeonExpertise in the surgical management of major abdominal hemorrhageExtensive background in diagnosing and treating major bleeding with numerous supporting publications and presentationsLeads EndoShunt's scientific efforts including grant applications, preclinical R&D protocol authorship, preclinical animal model testing, and relevant data publicationsWhile it's fun to celebrate our strengths, it's also important to recognize our areas of opportunity as well. We're partnering with the right organizations to ensure EndoShunt's long-term success.Greenlight Guru:Proven, validated and FDA-audited electronic Quality Management System (eQMS)Will ensure our team, product, and data are FDA and market readyHealth Policy Associates:Industry leading regulatory consulting firmResponsible for the FDA 510(k) clearance of our intended predicate device!Helping EndoShunt prepare for our FDA presubmission meeting and eventual clearance application in 2025.Medical Murray:Product development engineersIndustry leading ePTFE and catheter-based third party manufacturersEntirely US based supply chain with critical components sourced in Minnesota, and manufacturing, packaging, & sterilization in Illinois. US Army and Air Force:Hemorrhage from trauma is the leading cause of preventable death in military settingsOur R&D efforts will enable EndoShunt to generate cost effective data and potentially open revenue opportunities prior to FDA clearanceNote: future projections are not guaranteedWe have come a long way since our ideation in 2020. We've validated product-market fit in NSF I-Corps, produced working prototypes, filed our patents, proven effective hemorrhage control in a biological system, and have won numerous awards. To close the year, we will continue to make more robust our eQMS and execute our FDA Q-Sub meeting. In 2024 and beyond, we plan to carry out the necessary FDA testing requirements, apply for clearance, and prepare for our pilot launch in 2025. The funds raised on WeFunder will go directly towards the final iterative updates to our device, our qualification of our manufacturing supply chain, our FDA 510(k) pre-submission meeting, and the expansion of our executive team. In the future, EndoShunt will give the gift of time to trauma surgeons and, by helping us get to market, you can give the gift of life to their trauma patients.*Join us!Please reach out to Tyler Zanon (info@EndoShunt.com) with any questions or to request additional information in support of or supplemental to the information presented. The information presented on this page has not been reviewed by the FDA. Until regulatory clearance, EndoShunt makes no claims regarding the functionality or effectiveness of their device.*Please note future projections are not guaranteed.

## Team
- Tyler Zanon (Chief Executive Officer)
- Michael Finn-Henry (Chief Technology Officer)
- Dr. Jeremy Levin (Chief Scientific Officer)
- Dr. Milad Behbahaninia (Chief Medical Officer)